Click Therapeutics
Click Therapeutics Leadership & Management
What People Are Saying About Click Therapeutics
-
Strategic Vision & Planning: Public messaging consistently frames the mission as “software as prescription medical treatments” across a two‑pillar model (stand‑alone PDTs and Software‑Enhanced Drugs), reinforced by a 2025 brand refresh and aligned partner announcements. Communications emphasize a near‑term push to commercialize CT‑155 while maintaining a broader platform thesis.
-
Collaborative & Aligned Leadership: Partnerships and financing from Boehringer Ingelheim and Dassault/Medidata, alongside the transfer of CT‑155 commercialization rights, indicate coordination with stakeholders around a shared roadmap. The leadership roster spanning finance, technology, clinical, commercial, people, and legal functions signals structured cross‑functional alignment.
-
Strong Execution: Milestones such as FDA authorizations for CT‑132 and Rejoyn, plus progression of CT‑155 toward commercialization, demonstrate conversion of strategy into tangible outcomes. Acquisitions and ecosystem collaborations (e.g., AspyreRx, Ultrahuman) further illustrate operational follow‑through.
Click Therapeutics's Benefits
Hosts in-person all-hands meetings
Implements team-based strategic planning
Open office floor plan to encourage communication and collaboration
Uses an OKR operational model to clearly define goals and priorities
Utilizes an open door policy that encourages accessibility
